Niagen Bioscience (NASDAQ:NAGE) Cut to "Buy" at Wall Street Zen

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Friday.

Other research analysts have also issued research reports about the company. Roth Capital raised their price target on shares of Niagen Bioscience from $10.00 to $23.00 and gave the stock a "buy" rating in a report on Friday. Canaccord Genuity Group assumed coverage on Niagen Bioscience in a research report on Tuesday, May 27th. They issued a "buy" rating and a $13.00 price target on the stock.

Niagen Bioscience Stock Performance

NASDAQ:NAGE traded up $1.44 during midday trading on Friday, hitting $12.95. The company's stock had a trading volume of 1,221,258 shares, compared to its average volume of 850,456. The company's 50 day simple moving average is $8.56. Niagen Bioscience has a fifty-two week low of $2.31 and a fifty-two week high of $13.12. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of 76.18 and a beta of 1.94.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.